Sentences with phrase «inhibitor olaparib»

The FDA has expanded the approval of the PARP inhibitor olaparib (Lynparza) to include the treatment of patients with metastatic breast cancer who have a mutated BRCA gene.

Samples that were resistant and treated with the PARP inhibitor olaparib showed a higher percentage of RAD51 - positive cells than those that were PARP inhibition — sensitive (36 % vs 5 %; P =.0017).

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination with AZD1775, AZD5363, or AZD2014 in Advanced Solid Tumors - OLAPCO (OLAParib COmbinations)

Zhang's team began by combining the PARP inhibitor olaparib with 20 different helper compounds, and eventually discovered a family of drugs called BET inhibitors that work with olaparib to attack cancer cells.

«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).

In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.

It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.

Not exact matches

«This suggests that PGAM1 inhibitors can sensitize cancers to PARP inhibitors such as Olaparib, thereby expanding the benefits of PARP inhibitors to BRCA1 / 2 - proficient cancers, particularly triple - negative breast cancers that currently lack effective therapies,» says author Min Huang.

PARP (Poly ADP - Ribose Polymerase) inhibitors, such as olaparib, are targeted drugs that block an enzyme involved in many functions in the cell, including the repair of DNA damage.

«The results from this innovative clinical trial are very promising and highlight the potential for olaparib — and other PARP inhibitors — to treat a wide range of cancers.

An anti-angiogenic agent, or blood vessel inhibitor, called cediranib (which inhibits a protein known as VEGFR) and olaparib, a PARP inhibitor, are each clinically active in recurrent ovarian cancer.

The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone.

Based on these studies, the authors are designing a clinical trial to test whether DNA repair inhibitors, such as olaparib, are active against IDH1 - and IDH2 - mutant tumors.

Cancer Research UK, who did not fund the trial but have played an important role in the development of PARP inhibitors like olaparib, said the results highlighted their potential.

Treating women with olaparib, a new type of experimental drug called a PARP inhibitor, after their initial cancer treatment, may help prevent their ovarian cancer from coming back, according to a phase - II clinical trial led by UK scientists.

HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib.

Olaparib is a PARP inhibitor, which is already used to treat certain ovarian cancer patients and prevents damaged cancer cells from repairing themselves after chemotherapy or radiotherapy.

Professor Susan Short, member of NCRI's Radiotherapy Research Working Group, said: «We're just beginning to realise the full potential of PARP inhibitors to tackle many different types of cancer, so it's exciting to see that olaparib could potentially be used to treat glioblastoma in combination with chemotherapy and radiotherapy.